Systemic Inflammatory Response Syndrome Treatment & Management
- Author: Lewis J Kaplan, MD, FACS, FCCM, FCCP; Chief Editor: Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM more...
Treatment of systemic inflammatory response syndrome (SIRS) should focus on possible inciting causes. As the causes of SIRS include a wide range of disorders (eg, acute myocardial infarction, community-acquired pneumonia, pancreatitis), the appropriate interventions will likewise differ from patient to patient.
Studies of tumor necrosis factor–alpha (TNF-α) and interleukin-1 (IL-1) receptor antagonists, antibradykinin, platelet-activating factor receptor antagonists, and anticoagulants (antithrombin III) have not shown statistically significant benefits in SIRS. Variable results for sepsis and septic shock have been reported. These medications have no role in treating patients who meet criteria for SIRS only.
Patients who are hypotensive should receive intravenous fluids. In patients who are still hypotensive after adequate resuscitation, vasopressor agents should be administered while hemodynamic status is carefully monitored. All patients should have adequate intravenous access and commonly require 2 large-bore intravenous lines or a central venous catheter. For further details on the management of hypotension, please refer to Septic Shock.
The details of surgical management are site specific and are beyond the scope of this article. In general, however, abscesses or drainable foci of infection should be drained expeditiously to increase the efficacy of antibiotic therapy and to allow for adequate culture data. Patients with acute surgical issues (eg, ruptured appendix, cholecystitis) that cause SIRS should be treated with appropriate surgical measures. Prosthetic devices should be removed in a timely manner, when clinically feasible.
Enteral feedings supplemented with arginine and omega-3 fatty acids have been shown to be beneficial (decreased infectious complications, hospital days, and duration of mechanical ventilation) in critically ill patients. The ability to feed a patient and the route of nutrition vary based on the etiology of SIRS.
Because of the causative illness, many patients are bed bound. Therefore, deep venous thrombosis (DVT) and gastrointestinal stress ulcer prophylaxis should be considered to help prevent complications. Patients who are otherwise clinically stable and without contraindications to mobility should be permitted to perform activities as tolerated.
Requirements for patient transfer depend on a facility's capabilities and the comfort level of the admitting physicians for managing different medical conditions. The availability of specialists also affects transfer.
Empiric antibiotics are not indicated for all patients with systemic inflammatory response syndrome (SIRS). Indications for antibiotic therapy include the following:
Suspected or diagnosed infectious etiology (eg, urinary tract infection [UTI], pneumonia, cellulitis)
Neutropenia or other immunocompromised states
Asplenia - Due to the potential for overwhelming postsplenectomy infection (OPSI)
When feasible, culture specimens should always be obtained prior to initiating antibiotic therapy. Antibiotics administered prior to culturing may be a cause of sterile sepsis.
Empiric antibiotic therapy should be guided by available practice guidelines and knowledge of the local antibiogram, as well as the patient's risk factors for resistant pathogens and allergies. The key is to stop antibiotics when infection is ruled out or narrow the antibiotic spectrum once a pathogen is found.
Because of increasing bacterial resistance, broad-spectrum antibiotics should be initiated when an infectious cause for SIRS is a concern but no specific infection is diagnosed. With the increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in the community, vancomycin or another anti-MRSA therapy should be considered. Recent exposure to antibiotics (typically within 3 months) must be considered when choosing empiric regimens, because recent antibiotic therapy increases the risk for resistant pathogens.
Gram-negative coverage with cefepime, piperacillin-tazobactam, carbapenem (imipenem, meropenem, or doripenem), or a quinolone is reasonable. Care must be taken not to use an antibiotic to which the patient is allergic, which may be a second hit and lead to worsening SIRS; penicillin allergy is a particular concern, given its prevalence. A quinolone or aztreonam is a reasonable choice for gram-negative coverage in patients with a penicillin allergy. If aztreonam is used, gram-positive coverage (with an agent such as vancomycin) should be initiated as well, until culture results are available.
The FDA recently approved 3 new antibiotics, oritavancin (Orbactiv), dalbavancin (Dalvance), and tedizolid (Sivextro), for the treatment of acute bacterial skin and skin structure infections. These agents are active against Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant S aureus [MSSA, MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus group (includes Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), among others.
For complete drug information, including dosing, see the following monographs:
Antiviral and antifungal therapy
Antiviral therapy has no role in SIRS unless the patient is immunocompromised or presents for evaluation during influenza season and the clinical picture is consistent with influenza infection.
Empiric antifungal therapy (fluconazole or an echinocandin) can be considered in patients who have already been treated with antibiotics, patients who are neutropenic, patients who are receiving total parenteral nutrition (TPN), or patients who have central venous access in place.
The inflammatory mediators and receptors associated with infectious insults (ie, septic shock) are the same as those linked to noninfectious insults (ie, trauma, inflammatory conditions, ischemia).
Steroids for sepsis and septic shock have been extensively studied, but no investigations specific to systemic inflammatory response syndrome (SIRS) have been performed to date.
The initial research in sepsis and septic shock showed a trend toward worse outcomes when treating with high doses of steroids (methylprednisolone sodium succinate 30 mg/kg every 6 h for 4 doses) compared with placebo. However, research into low-dose steroids (200-300 mg of hydrocortisone for 5-7 days) improved survival and the reversal of shock in vasopressor-dependent patients.
Low-dose steroids should be considered on an individual basis for patients with refractory hypotension (ie, septic shock) despite adequate fluid resuscitation and appropriate vasopressor administration. Prior to initiating steroid therapy, however, physicians must consider the potential risks of steroids, such as stress ulcers and hyperglycemia.
Similarly, in the critically ill vasoplegic patient (ie, hypotensive despite fluid resuscitation and vasopressor therapy), the use of vasopressin (0.01-0.02 mcg/kg/h) may be beneficial in decreasing vasopressor requirements without causing more ischemia. Its effects on mortality have not been proven.
Current data do not support using adrenocorticotropic hormone (ACTH) stimulation testing to determine which patients should receive steroid therapy. Patients receiving steroids require careful monitoring for hyperglycemia.
Hyperglycemia, a common laboratory finding in systemic inflammatory response syndrome (SIRS), even in individuals without diabetes, has numerous deleterious systemic effects.[28, 29]
An increase in counterregulatory hormones, namely cortisol and epinephrine, and relative hypoinsulinemia lead to increased hepatic glucose production, increased peripheral insulin resistance, and increased circulating free fatty acids. This has direct inhibitory action on the immune system. Oxidative stress and endothelial cell dysfunction, along with proinflammatory cytokines (IL-6, IL-8, TNF-α) and other secondary mediators (NF-kB) have all been implicated as causes of cellular injury, tissue damage, and organ dysfunction in patients with hyperglycemia.
Intensive control of blood glucose levels has been shown to diminish in-hospital morbidity and mortality in the surgical and medical intensive care setting. Various trials have demonstrated that glycemic control with insulin improves patient outcomes (including renal function and acute renal failure), reduces the need for red blood cell transfusions, reduces the number of days in the ICU, lowers the incidence of critical-illness polyneuropathy, and decreases the need for prolonged mechanical ventilation.
Van den Berghe et al reported a reduction of in-hospital mortality rates with intensive insulin therapy (maintenance of blood glucose at 80-110 mg/dL) by 34%. The greatest reduction in mortality involved deaths due to multiple-organ failure with a proven septic focus. Subsequent studies by this group and others have failed to demonstrate distinct outcome benefit from tight glucose control, mainly because the complication rate for hypoglycemia and hypokalemia complicate its effects. Presently, the Surviving Sepsis guidelines recommend keeping glucose levels at less than 180 mg/dL.
Supplemental oxygen should be provided to any patient who demonstrates an increased oxygen requirement or decreased oxygen availability. Oxygen can be provided via nasal cannula or mask, although in certain situations, ventilator support may be required to maximize oxygen delivery.
Supplying supraphysiologic oxygen has shown mixed results in a multitude of studies. Providing too much oxygen in a patient with severe chronic obstructive pulmonary disease (COPD) should be avoided because it can depress the respiratory drive.
Patients who do not respond to increased oxygen supply have a poor prognosis. Patients with associated respiratory failure who require mechanical ventilation should be treated with low tidal volume mechanical ventilation (6 mL/kg).
Consultations vary depending on the admitting physician's training and the cause of systemic inflammatory response syndrome (SIRS); for example, cardiology consultation for acute myocardial infarction or gastroenterology for acute GI bleeding. Patients with potential surgical issues should undergo a surgical evaluation, often in the emergency department, early in the course of their illness.
Consider consultation with an intensivist, if one is available. If organ dysfunction develops, the intensivist or a consultant specialist in that organ system should be involved.
Early consultation with an expert in infectious diseases is particularly helpful for patients who are immunocompromised, regardless of the cause (eg, human immunodeficiency virus [HIV] infection, acquired immunodeficiency syndrome [AIDS], malignancy, solid organ transplantation). This specialist can also provide guidance in situations in which patients are not responding to standard antibiotic therapy, have multiple drug allergies, or are infected with multidrug-resistant organisms or when a diagnosis is still uncertain.
[Guideline] Bone RC, Balk RA, Cerra FB. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992. 101:1644-1655. [Medline].
Bae JS. Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Arch Pharm Res. 2012 Sep. 35(9):1511-23. [Medline].
Wang KY, Yu GF, Zhang ZY, Huang Q, Dong XQ. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clin Chim Acta. 2012 Nov 12. 413(21-22):1737-41. [Medline].
Fung YL, Fraser JF, Wood P, Minchinton RM, Silliman CC. The systemic inflammatory response syndrome induces functional changes and relative hyporesponsiveness in neutrophils. J Crit Care. 2008 Dec. 23(4):542-9. [Medline].
Dremsizov T, Gilles C, Kellum JA. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?. Chest. 2006. 129:965-978.
Thoeni RF. The revised atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. Radiology. 2012 Mar. 262(3):751-64. [Medline].
Rangel-Fausto MS, Pittet D, Costigan M. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995. 273:117-123. [Medline].
Pittet D, Rangel-Fausto MS, Li N. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Int Care Med. 1995. 21:302-309.
Heffner AC, Horton JM, Marchick MR, Jones AE. Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department. Clin Infect Dis. 2010 Mar 15. 50(6):814-20. [Medline].
Comstedt P, Storgaard M, Lassen AT. The Systemic Inflammatory Response Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study. Scand J Trauma Resusc Emerg Med. 2009 Dec 27. 17(1):67. [Medline]. [Full Text].
Angus DC, Linde-Zwirble WT, Lidicker J. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001. 29:1303-1310. [Medline].
Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014 Apr 2. 311(13):1308-16. [Medline].
Shapiro N, Howell MD, Bates DW. The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med. 2006. 48:583-590.
Sinning JM, Scheer AC, Adenauer V, Ghanem A, Hammerstingl C, Schueler R, et al. Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J. January 2012. pending:1-10. [Medline]. [Full Text].
Nierhaus A, Klatte S, Linssen J, Eismann NM, Wichmann D, Hedke J. Revisiting the white blood cell count: immature granulocytes count as a diagnostic marker to discriminate between SIRS and sepsis--a prospective, observational study. BMC Immunol. 2013. 14:8. [Medline].
Lai CC, Chen SY, Wang CY, Wang JY, Su CP, Liao CH, et al. Diagnostic value of procalcitonin for bacterial infection in elderly patients in the emergency department. J Am Geriatr Soc. 2010 Mar. 58(3):518-22. [Medline].
Jekarl DW, Lee SY, Lee J, Park YJ, Kim Y, Park JH, et al. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. Diagn Microbiol Infect Dis. 2013 Apr. 75(4):342-7. [Medline].
Hoeboer SH, Alberts E, van den Hul I, Tacx AN, Debets-Ossenkopp YJ, Groeneveld AB. Old and new biomarkers for predicting high and low risk microbial infection in critically ill patients with new onset fever: A case for procalcitonin. J Infect. 2012 Jan 8. [Medline].
Arkader R, Troster EJ, Lopes MR. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child. 2006. 91:117-120.
Selberg O, Hecker H, Martin M. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentration of procalcitonin, protein complement 3a and interleukin-6. Crit Care Med. 2000. 28:2793-2798.
Balci C, Sivaci R, Akbulut G, Karabekir HS. Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. J Int Med Res. 2009 Nov-Dec. 37(6):1709-17. [Medline].
Hohn A, Schroeder S, Gehrt A, Bernhardt K, Bein B, Wegscheider K, et al. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infect Dis. 2013 Apr 1. 13:158. [Medline]. [Full Text].
Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C, Pape HC. Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state?. J Trauma. 2008 Sep. 65(3):646-52. [Medline].
Bracho-Riquelme RL, Reyes-Romero MA. Leptin in sepsis: a well-suited biomarker in critically ill patients?. Crit Care. 2010. 14(2):138. [Medline].
Yousef AA, Amr YM, Suliman GA. The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-alpha in critically ill patients: a prospective observational study. Crit Care. 2010. 14(2):R33. [Medline].
[Guideline] Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013 Feb. 39(2):165-228. [Medline].
Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009 Jun 10. 301(22):2362-75. [Medline].
Jeschke MG, Klein D, Herndon DN. Insulin therapy improves systemic inflammatory reaction to severe trauma. Ann Surg. 2004. 239:553-560.
Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004. 79:992-1000. [Medline].
Van den Berghe G, Wilmer A, Hermans G. Intensive insulin therapy in the medical ICU. N Eng J Med. 2006. 354:449-61. [Medline].